Using Quantitative Systesm Pharmacology to optimize amyloid‐tau combination clinical trials on Alzheimer's Disease

The simulations suggest a complex interaction between disease state, amyloid and tau baseline and to a lesser extent APOE genotype for the effect of pathological tau reduction on functional clinical scales. Failure to take this interaction into account might lead to reduced clinical signals in tau therapeutics drug development. Importantly, this model can also be used for appropriate combination therapy of amyloid and tau therapeutics against the background of comedications in AD patients.